Drug Information

Drug (ID: DG00470) and It's Reported Resistant Information

• Name: Dapsone/Rifampin
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (2 diseases)
  COVID-19 [ICD-11: 1D92]; [1]
  Leprosy [ICD-11: 1B20]; [2]

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-01: Infectious/parasitic diseases

Leprosy [ICD-11: 1B20]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Dihydrofolate reductase (DHFR) [2]

• Molecule Alteration: Missense mutation; p.P55R
• Resistant Disease: Leprosy [ICD-11: 1B20.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Mycobacterium leprae isolates; 1769
• In Vivo Model: Footpad granuloma from M. leprae-infected nude mice model; Mus musculus
• Experiment for Molecule Alteration: PCR and single-stranded conformational polymorphism (SSCP) assay
• Experiment for Drug Resistance: Mouse footpad assay
• Mechanism Description: The mutations genes reported in this study have been demonstrated to be responsible for drug resistance by mouse footpad assay.

References

• Ref 1: Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies Nat Med. 2021 Apr;27(4):717-726. doi: 10.1038/s41591-021-01294-w. Epub 2021 Mar 4.
• Ref 2: Mutations in genes related to drug resistance in Mycobacterium leprae isolates from leprosy patients in Korea. J Infect. 2005 Jan;50(1):6-11. doi: 10.1016/j.jinf.2004.03.012.